Increasing the Time Interval Suppresses Adverse Effects After Concomitant Use of Nafamostat Mesylate and Levocarnitine in Dialysis Patients: Case Series.

PURPOSE: This is a series of reports describing how increasing the time interval between the administration of nafamostat mesylate (NM) and levocarnitine can suppress adverse reactions in maintenance hemodialysis patients after medication.

METHODS

Clinical assessments and medical record collection were conducted by nephrologists and nurses, while laboratory tests were performed by specialist doctors.

FINDINGS: Increasing the time interval between NM and levocarnitine administration (15-25 minutes) reduced adverse drug reactions, including nausea and vomiting, in 4 patients.

IMPLICATIONS: This may provide clinical doctors with new insights and research directions when using levocarnitine and NM for dialysis treatment.